USA TODAY  by Samwar Fallah and Gregg Zoroya                                              March 28, 2015

MONROVIA, Liberia — Aid workers are rushing into neighboring Guinea to try to stanch a worrisome rise in cases of the deadly Ebola virus, which has been slowed in Sierra Leone and been all but eradicated here.

A man crouches next to the grave of an unknown man (L) at the National Memorial Cemetry on Disco Hill, Margibi County, Liberia, 11 March 2015. The cemetery was established to provide a dignified burial for ebola victims and bring an end to the usual cremation of victims during the outbreak. Liberia on 11 March observed a National Memorial Day to remember, honour, and decorate the graves of the dead. The government of Liberia on 05 March discharged the last ebola patient, thus raising the hopes of the end of the epidemic. EPA/AHMED JALLANZO ORG XMIT: MON107(Photo: AHMED JALLANZO, EPA)

The mission is urgent because the coming rainy season could hamper travel to remote villages where the disease continues to emerge.

THE GUARDIAN by Lisa O'Carroll                                                           March 27, 2015

Ebola should be seen as an early wake-up call to world leaders of the potential for an international health disaster in the same way that the 1998 US embassy bombings highlighted the possibility of further attacks by al-Qaida, a leading British medic in Sierra Leone has warned.

Dr Oliver Johnson has called for “a big political shakeup” at the World Health Organisation and says Britain’s Department for International Development must decide whether to “nationalise” aid and deploy the army the next time a humanitarian emergency hits.

EUROSURVEILLANCE  by  K. Kaasik-Aaslav and  D. Coulombier                                   March 26, 2015

Upon entering what seems to be the tail of the epidemic and, as in any such moment, the ‘Ebola endgame’ strategy requires adaptation to the heterogeneity of the epidemiological situation. The tools for EVD control need to be fine-tuned and the commitment from the teams supporting local authorities in affected countries needs to be sustained.

While the pressure on clinical and laboratory expertise gradually decreases, the demand shifts towards field epidemiologists to assist local public health experts and support community workers to engage in active surveillance and to monitor remaining transmission chains in affected communities.

EUROSURVEILLANCE by I. Goodfellow, C. Reusken, and M. Koopmans  

  March 26, 2015                                                              

The Ebola virus epidemic in West Africa is on the brink of entering a second phase in which the (inter)national efforts to slow down virus transmission will be engaged to end the epidemic. The response community must consider the longevity of their current laboratory support, as it is essential that diagnostic capacity in the affected countries be supported beyond the end of the epidemic.

The emergency laboratory response should be used to support building structural diagnostic and outbreak surveillance capacity.

The slowdown in the West African Ebola epidemic is welcome news and reason to be hopeful—but it’s also creating a new problem. With fewer new cases occurring, it is becoming more and more difficult to test vaccines and drugs. As a result, conflicts are looming over who can test Ebola drugs and vaccines in Guinea and Sierra Leone.

An Ebola treatment unit in Guinea.Samuel Hanryon/MSF

In Guinea, a large consortium that includes Doctors Without Borders (MSF) and the World Health Organization (WHO) vaccinated the first volunteers at risk of Ebola on Monday in a big trial of a vaccine produced by Merck and NewLink Genetics. But the team feels threatened because researchers at the U.S. National Institutes of Health (NIH) are looking to move another vaccine study from Liberia, where the epidemic has come to a virtual standstill, to Guinea.

SCIENCE DAILY                                                March 26, 2015

(Scroll down for complete paper.)
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus.

The vaccine, described today (March 26, 2015) in the journal Science, was developed by a group led by Yoshihiro Kawaoka, a University of Wisconsin-Madison expert on avian influenza, Ebola and other viruses of medical importance. It differs from other Ebola vaccines because as an inactivated whole virus vaccine, it primes the host immune system with the full complement of Ebola viral proteins and genes, potentially conferring greater protection.

"In terms of efficacy, this affords excellent protection," explains Kawaoka, a professor of pathobiological sciences in the UW-Madison School of Veterinary Medicine and who also holds a faculty appointment at the University of Tokyo. "It is also a very safe vaccine."

NEW YORK - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday.

The two vaccines, each given in a single injection, are being tested for safety and efficacy on more than 600 people in Liberia in a mid-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a branch of NIH.

The Ebola epidemic that began in West Africa one year ago has killed more than 10,200 people, but a decline in new cases in the most affected countries, Liberia, Guinea and Sierra Leone, has led to hopes that it may be ending.

Based on the encouraging safety results, the study may now advance to the next phase of efficacy testing, in which additional volunteers are injected with the GSK vaccine, the NewLink vaccine, or a dummy shot and assessed to see whether their immune system responds by producing anti-Ebola antibodies.

SCIENCE NEWS  by Ashley Yaeger                                                      March 26, 2015

(Scroll down for full study.)

The virus causing the current Ebola epidemic in West Africa is not evolving as quickly as some scientists had suggested.

REGULAR RATE  A genetic analysis suggests that the Ebola virus, shown here in orange, is not evolving as fast as expected.

In a paper last August, researchers reported that the virus (Zaire ebolavirus) was altering its genes almost twice as fast as it had during previous Ebola outbreaks in Central Africa (SN: 9/20/14, p. 7). However, a new genetic analysis shows that the virus is mutating at roughly the same rate as in past outbreaks, researchers report online March 26 in Science. The finding suggests the virus has not become more virulent or transmissible during the West Africa outbreak.

NATIONAL PUBLIC RADIO  by Poncie Rutsch                                                      March 25, 2015
From more than 900 miles away, Kpetermeni Siakor helped get volunteers to the right neighborhoods in his native Liberia during the height of the Ebola epidemic.

Kpetermeni Siakor (left), a Liberian who is studying in Ghana, used crowdsourcing software to help out during the Ebola epidemic. Courtesy of Ashesi University College

He did it with Ushahidi, crowdsourcing software that was developed in Kenya in 2008, when the country experienced a wave of post-election violence. The word Ushahidi means testimony in Swahili.

"The government had shut down internet connections and radio stations, so Ushahidi was born out of the need to let people know what is happening," says Siakor, 26. He's a computer science student at Ashesi University College in Accra, Ghana, and receives financial support from the MasterCard Foundation Scholars Program.

CLICK HERE - RECORDED VIDEO - Dr. Gavin Macgregor-Skinner

ctvnews.ca - March 23, 2015

Public health emergency expert Dr. Gavin Macgregor-Skinner discusses a new report saying faster action would have stopped the spread of Ebola.

CLICK HERE - MSF REPORT AND RELATED INFORMATION

TIME MAGAZINE  by Alexandra Sifferlin                                             March 25, 2015
An efficacy trial for an Ebola vaccine launched in Guinea on Wednesday.

 A health worker prepares a vaccination on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus.

The vaccine, VSV-EBOV, was developed by the Public Health Agency of Canada and has already shown positive results in smaller safety trials. NewLink Genetics and Merck are collaborating on the vaccine, and the Guinean government and World Health Organization (WHO) are leading the trial, which is taking place in Basse-Guinée, a community where many Ebola cases spread.

LIVE SCIENCE       by Agata Blaszczak Boxe                                               March 25, 2015

Young children who are infected with Ebola may be more likely to die from the virus than older children or adults who are infected, according to a new study.

The disease has killed about 90 percent of infected children under age 1, and about 80 percent of kids ages 1 to 4 who have been infected. Older children who have been infected with Ebola may have a much better chance of surviving....

"The very youngest of children — neonates  —appear to have the worst outcomes from Ebola," study co-author Dr. Robert Fowler, an associate professor of critical-care medicine at the University of Toronto, said in a statement. (Neonates, or newborns, are babies younger than 1 month.)

PLOS MEDICINE by Mark J. Siedner, Lawrence O. Gostin, Hilarie H. Cranmer,and John D. Kraemer                        March 24, 2015

In-depth paper on lessons learned from the West Africa Ebola outbreak

WHO  WEEKLY SITUATION REPORT                                         March 25, 2015

Summary 

NEW YORK TIMES  by Sheri Fink                                                            March  25, 2015

Worries have widened in recent days over the number of people in Liberia who may have been exposed to the country’s first Ebola case in more than two weeks, a street vendor who lived in a one-bathroom house shared with 52 others in a Monrovia suburb and who had sold food at a school where more than 1,900 students are enrolled.